정보마당

No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

MoA

Indication

Stage

Value

(USD Mn)

1

7/1

Takeda

Insilico medicine

‘Pharma.AI’ platform

AI-driven drug discovery platform

n/d

n/d

Discovery

600

2

7/1

Fosun Wanbang Pharma Group

Shanghai Junshi Biosciences

Roconkibart

αIL-17A mAb

Immunology

Plaque psoriasis

Registration
(China)

166

3

7/2

Astrazeneca

CSPC Pharmaceutical

-

siRNA drug discovery platform + extrahepatic delivery toolkit

Genitourinary

Kidney diseases

Discovery

1,770

4

7/2

Lonza

Nona Biosciences

TfR1 BBB shuttle

TfR1-binding single-domain VHH technology

Neurology

CNS diseases

Preclinical

n/d

5

7/3

QuantumCell

AlzeCure Pharma

ACD856

TrkA/TrkB modulator

Neurology

Alzheimer’s disease

Phase 1

2,200+

6

7/3

Sanyou Biopharmaceutical

Guangzhou Baiyunshan Xihe Health Pharmaceutical

‘AI-STAL’ platform, ‘SAI-DA’ platform

AI-driven molecular discovery + radionuclide labeling / radiopharmaceutical medicine platform

Oncology

Cancer

Discovery

n/d

7

7/6

Genentech
(Roche)

Astex Pharmaceuticals

n/d

Selective inhibitor against cell-cycle-dependent regulator

Oncology

Breast cancer

Discovery

490

8

7/7

Boehringer Ingelheim

Prime Vector Technologies

Orf virus (ORFV) platform

Viral vector-mediated tumor antigen delivery

Oncology

Cancer

Preclinical

n/d

9

7/8

AstraZeneca

Chia Tai Tianqing Pharmaceutical
(Sino Biopharmaceutical)

TQC3721

PDE3/4 dual inhibitor

Immunology

COPD

Phase 3

2,100

10

7/9

PegBio Co.

Rani Therapeutics Holdings

‘RaniPill®’ platform

Rani’s oral delivery platform + PegBio’s metabolic pipeline

Metabolic disorder

Obesity

Preclinical

n/d

11

7/14

Bora Pharmaceuticals

Insilico medicine

‘Pharma.AI’ platform

AI-driven drug discovery platform

n/d

n/d

Discovery

2,500+

12

7/14

AstraZeneca

Dizal Pharmaceutical

Zegfrovy

EGFR exon 20 insertion mutation inhibitor

Oncology

NSCLC

Marketed

1,500

13

7/14

Spero Therapeutics

Innovent Biologics

IBI-355

αCD40L mAb

Immunology

Sjögren's syndrome

Phase 1

1,100

14

7/16

Mirador Therapeutics

Kira Pharmaceuticals

KP301

KP402

αC5a mAb

C5a receptor agonist

Immunology

Hematology

ANCA-associated vasculitis (AAV)

Complement-mediated diseases

Preclinical

Preclinical

n/d

15

7/17

Dimerix Ltd.

Mission Therapeutics

MTX652

USP30 inhibitor

Genitourinary

Acute kidney injury

Phase 1

292

16

7/20

Incyte

Halozyme Therapeutics

ENHANZE®

SC formulation of INCA033989 enabled by ENHANZE®

Hematology

mutCALR+ myeloproliferative neoplasms (MPNs)

Phase 1

n/d

17

7/21

Genentech
(Roche)

MaxCyte

‘ExPERT GTx®’ platform

Ex vivo cell-engineering electroporation platform

n/d

n/d

Discovery

n/d

18

7/21

Whitehawk Therapeutics*

Akari Therapeutics

Akari: PH1 spliceosome-modulating payload tech.

Whitehawk: TOP1i ADC platform

Collaboration: Dual-payload ADC tech. development

Oncology

Cancer

Discovery

n/d

19

7/21

Kaveri Therapeutics**

Lupin

LNP7457

LNP8701

PRMT5 inhibitor

SOS1 inhibitor

Oncology

Oncology

Solid tumors

Solid tumors

Phase 1

Phase 1

n/d

20

7/22

Kairos Pharma*

Bayer

Kairos: Carotuximab(αCD105 neutralizing mAb; CD105/BMP signaling inhibitor)

Bayer: XOFIGO(Radium Ra 223 dichlorid)

Collaboration: ENV-105 + XOFIGO combination

Oncology

Bone-metastatic mCRPC

Phase 2

n/d

21

7/23

Synaptiq Therapeutics**

Nobias Therapeutics

SYN-001

mGluR modulator

Neurology

22q11.2 Deletion Syndrome

Phase 2

n/d

22

7/27

Sinopharm*

Harbour Biomed

Harbour BioMed: Harbour Mice® antibody discovery platform

Sinopharm: clinical development, large-scale manufacturing, commercialization

Oncology,
Immunology & Inflammation

n/d

Discovery

n/d

23

7/28

CORE Biomedicine

Eisai

n/d

Precision oncology programs

Oncology

Cancer

Preclinical

n/d

24

7/29

Vertex Pharmaceuticals*

AbCellera

n/d

Multispecific TCE platform

Immunology

Autoimmune disease

Discovery

n/d

25

7/30

J&J

Sail Biomedicines

n/d

In vivo CAR-T

Immunology

Autoimmune disease

Preclinical

3,505

No

Date

Acquires

Issuer

Assets

MoA

Indications

Status

Value

(USD Mn)

1

7/6

Vertex Pharmaceuticals

Crinetics Pharmaceuticals

PALSONIFY®

Atumelnant

SSTR2 agonists

Adrenocorticotropic hormone (ACTH) receptor antagonist

Endocrinology

Endocrinology

Acromegaly

Congenital adrenal hyperplasia

Marketed

Phase 3

10,000

2

7/6

Novartis

Myricx Bio

n/d

n/d

B7-H3-NMTi ADC

HER2-NMTi ADC

Oncology

Oncology

Solid tumors

Solid tumors

Preclinical

Preclinical

1,500

3

7/8

Scipher Medicine

Chemomab Therapeutics

Nebokitug

αCCL24 mAb

Immunology

Rheumatoid arthritis

Phase 2

180

4

7/14

Jasper Therapeutics

Kira Pharmaceuticals

KP104

KP701

αC5/CFH bifunctional antibody

CD79B × CD32B BsAbs

Hematology

Immunology

Paroxysmal nocturnal
hemoglobinuria (PNH)

B-cell–mediated autoimmune disorders

Phase 2

Preclinical

150+

5

7/16

Eli Lilly

AtaiBeckley

BPL-003

VLS-01

5-MeO-DMT–based 5-HT1A/2A agonist

DMT-based 5-HT agonist

Neurology

Neurology

Depression

Depression

Phase 3

Phase 2

3,800

6

7/27

Argenx

Forte Biosciences

FB102

αCD122 mAb

Immunology

Immunology

Vitiligo

Celiac disease

Phase 1b

Phase 2

2,200